BLUSPRING and SURAKSHA, both in Medical Laboratories. Monthly data through 2026-10-09. Change the comparison →
Share price change since Jun '25, the first month all 2 have a price: BLUSPRING +94%, SURAKSHA -3%.
Rebased at 2025-06. Monthly closes from each company's history.
Months with a missing value are left as gaps.
Each cell is the company's percentile rank among its own sector peers that month. Darker is higher-ranked. Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Percentiles use today's listed companies in the sector and need at least 5 peers with a value.
| Metric | BLUSPRING | SURAKSHA |
|---|---|---|
| Share Price | ₹146.96 | ₹316.25 |
| Market Cap | ₹2185 cr | ₹1655 cr |
| P/E | 112.2x | 44.7x |
| P/B | 2.5x | 6.6x |
| P/S | 0.9x | 5.3x |
| ROCE | 6.0% | 18.0% |
| ROE | 2.2% | 14.9% |
| Operating margin | 2.2% | 34.0% |
| Revenue (TTM), indexed to 100 | ₹2369 cr | ₹315 cr |
| Net Profit (TTM) | ₹19 cr | ₹37 cr |
| Debt / Equity | 0.1x | 0.5x |
| Cash Conversion Cycle | 90d | -84d |
| Promoter holding | 58.0% | 49.1% |
| FII Holding | 5.7% | 13.5% |
| DII Holding | 8.6% | 23.2% |
| 12M momentum | 85.4% | -0.5% |
| Drawdown from Peak | 0.0% | -15.8% |
| Cash conversion (3Y) | — | 2.2x |
| Interest cover | 1.7x | 4.5x |
| Share Count Change (1Y) | 0.0% | 0.0% |
| Volatility (1Y) | 57.3% | 34.4% |
Latest month in the data: 2026-10. Highlight marks the higher value, or the lower value for P/E, P/B, P/S, debt, working-capital days, share count change and volatility. It marks a number, not a better investment.
Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment. Not investment advice; ApnaFunda is not a SEBI-registered research analyst.